Objective  To systematically evaluate the current status of hepatic encephalopathy (HE) and its influencing factors in patients after transjugular intrahepatic portosystemic shunt (TIPS).

Methods  Cochrane Library, PubMed, Embase, Web of Science, CINAHL , CNKI, VIP , CBM, WanFang database were searched from inception to October 20, 2024. Meta-analysis was performed using Stata 14.0 and RevMan 5.3 software.

Results  A total of 40 original studies involving 8,509 patients were included. The results of Meta-analysis showed that the incidence of HE in patients after TIPS was 31%[95%CI(28%, 34%)], and age [OR=1.22, 95%CI(1.15, 1.29)], MELD score [OR=1.46, 95%CI(1.29, 1.65)], preoperative blood creatinine [OR=1.27, 95%CI(1.14, 1.41)], Child-Pugh classification [OR=2.83, 95%CI(1.56, 5.13)], preoperative blood ammonia [OR=1.25, 95%CI(1.18, 1.33)], Child-Pugh score [OR=1.21, 95%CI(1.08, 1.35)], preoperative bilirubin [OR=1.35, 95%CI(1.11, 1.65)], preoperative sodium [OR=1.30, 95%CI(1.16, 1.45)], and a history of preoperative HE [OR=2.00, 95%CI(1.06, 3.76)] were the influence factors for the development of HE in patients after TIPS.

Conclusion  The incidence of HE in post-TIPS patients is high, and clinicians should identify and intervene early to minimize or delay the occurrence of HE in patients after the TIPS procedure referring to the influence factors.

1.Lv Y, Fan D, Han G. Transjugular intrahepatic portosystemic shunt for portal hypertension: 30 years experience from China[J]. Liver Int, 2023, 43(1): 18-33. DOI: 10.1111/liv.15313.

2.Zhu Y, Wang X, Xi X, et al. Emergency transjugular intrahepatic portosystemic shunt: an effective and safe treatment for uncontrolled variceal bleeding[J]. J Gastrointest Surg, 2019, 23(11): 2193-2200. DOI: 10.1007/s11605-019-04146-8.

3.Wang LJ, Yao X, Qi Q, et al. Prevention and treatment of hepatic encephalopathy during the perioperative period of transjugular intrahepatic portosystemic shunt[J]. World J Gastrointest Surg, 2023, 15(8): 1564-1573. DOI: 10.4240/wjgs.v15.i8.1564.

4.陈杨, 刘家成, 杨崇图, 等. 经颈静脉肝内门体分流术后肝性脑病预后因素研究进展[J]. 介入放射学杂志, 2022, 31(3): 301-306. [Chen Y, Liu JC, Yang CT, et al. Research progress in studying the prognostic factors of hepatic encephalopathy occurring after transjugular intrahepatic portosystemic shunt[J]. Journal of Interventional Radiology, 2022, 31(3): 301-306.] DOI: 10.3969/j.issn.1008-794X.2022.03.020.

5.Hernández-Gea V, Procopet B, Giráldez Á, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study[J]. Hepatology, 2019, 69(1): 282-293. DOI: 10.1002/hep.30182.

6.Tripathi D, Stanley AJ, Hayes PC, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension[J]. Gut, 2020, 69(7): 1173-1192. DOI: 10.1136/gutjnl-2019-320221.

7.Gairing SJ, Müller L, Kloeckner R, et al. Post-TIPSS hepatic encephalopathy-current knowledge and future perspectives[J]. Aliment Pharmacol Ther, 2022, 55(10): 1265-1276. DOI: 10.1111/apt.16825.

8.Boike JR, Thornburg BG, Asrani SK, et al. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension[J]. Clin Gastroenterol Hepatol, 2022, 20(8): 1636-1662. DOI: 10.1016/j.cgh.2021.07.018.

9.Butt Z, Jadoon NA, Salaria ON, et al. Diabetes mellitus and decompensated cirrhosis: risk of hepatic encephalopathy in different age groups[J]. J Diabetes, 2013, 5(4): 449-455. DOI: 10.1111/1753-0407.12067.

10.Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts[J]. Am J Gastroenterol, 2008, 103(11): 2738-2746. DOI: 10.1111/j.1572-0241.2008.02102.x.

11.Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, et  al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis[J]. Hepatol Int, 2018, 12(4): 377-386. DOI: 10.1007/s12072-018-9875-9.

12.Casadaban LC, Parvinian A, Minocha J, et al. Clearing the confusion over hepatic encephalopathy after TIPS creation: incidence, prognostic factors, and clinical outcomes[J]. Dig Dis Sci, 2015, 60(4): 1059-1066. DOI: 10.1007/s10620-014-3391-0.

13.李柄辉,訾豪,李路遥,等. 医学领域一次研究和二次研究的方法学质量(偏倚风险)评价工具[J]. 医学新知, 2021, 31(1): 51-58. [Li BH, Zi H, Li LY, et al. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?[J]. Yixue Xinzhi Zazhi, 2021, 31(1): 51-58.] DOI: 10.12173/j.issn.1004-5511.2021.01.07.

14.Borenstein M, Hedges LV, Higgins JP, et al. A basic introduction to fixed-effect and random-effects models for Meta-analysis[J]. Res Synth Methods, 2010, 1(2): 97-111. DOI: 10.1002/jrsm.12.

15.Dettori JR, Norvell DC, Chapman JR. Fixed-effect vs random-effects models for Meta-analysis: 3 points to consider[J]. Global Spine J, 2022, 12(7): 1624-1626. DOI: 10.1177/ 21925682221110527.

16.Berlioux P, Robic MA, Poirson H, et al. Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests[J]. Hepatology, 2014, 59(2): 622-629. DOI: 10.1002/hep.26684.

17.Chen Q, Zhang Y, Yue ZD, et al. High-mobility group protein B1: a predictive biomarker for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. J Hepatobiliary Pancreat Sci, 2020, 27(8): 522-530. DOI: 10.1002/jhbp.770.

18.Dissegna D, Sponza M, Falleti E, et al. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis[J]. Eur J Gastroenterol Hepatol, 2019, 31(5): 626-632. DOI: 10.1097/meg.0000000000001342.

19.Fonio P, Discalzi A, Calandri M, et al. Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification[J]. Radiol Med, 2017, 122(9): 713-721. DOI: 10.1007/s11547-017-0770-6.

20.He F, Dai S, Xiao Z, et al. Pathological predictors of shunt stenosis and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Biomed Res Int, 2016, 16(2): 325-333. DOI: 10.1155/2016/3681731.

21.Lin X, Gao F, Wu X, et al. Efficacy of albumin-bilirubin score to predict hepatic encephalopathy in patients underwent transjugular intrahepatic portosystemic shunt[J]. Eur J Gastroenterol Hepatol, 2021, 33(6): 862-871. DOI: 10.1097/meg.0000000000001801.

22.Liu J, Zhou C, Wang Y, et al. The combination of Child-Pugh score and quantitative CT-based spleen volume could predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation[J]. Abdom Radiol (NY), 2021, 46(7): 3464-3470. DOI: 10.1007/s00261-021-02972-6.

23.Masson S, Mardini HA, Rose JD, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience[J]. QJM, 2008, 101(6): 493-501. DOI: 10.1093/qjmed/hcn037.

24.Merola J, Chaudhary N, Qian M, et al. Hyponatremia: a risk factor for early overt encephalopathy after transjugular intrahepatic portosystemic shunt creation[J]. J Clin Med, 2014, 3(2): 359-372. DOI: 10.3390/jcm3020359.

25.Nardelli S, Gioia S, Pasquale C, et al. Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Am J Gastroenterol, 2016, 111(4): 523-528. DOI: 10.1038/ajg.2016.29.

26.Nardelli S, Lattanzi B, Torrisi S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement[J]. Clin Gastroenterol Hepatol, 2017, 15(6): 934-936. DOI: 10.1016/j.cgh.2016.10.028.

27.Rowley MW, Choi M, Chen S, et al. Race and gradient difference are associated with increased risk of hepatic encephalopathy hospital admission after transjugular intrahepatic portosystemic shunt placement[J]. J Clin Exp Hepatol, 2018, 8(3): 256-261. DOI: 10.1016/j.jceh.2017.12.003.

28.Schindler P, Seifert L, Masthoff M, et al. TIPS modification in the management of shunt-induced hepatic encephalopathy: analysis of predictive factors and outcome with shunt modification[J]. J Clin Med, 2020, 9(5): 567. DOI: 10.3390/jcm9020567.

29.Teng D, Zuo H, Liu L, et al. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment[J]. Virol J, 2018, 15(1): 151. DOI: 10.1186/s12985-018-1067-7.

30.Tong H, Gan C, Wei B, et al. Risk factors for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation in patients with liver cirrhosis[J]. J Dig Dis, 2021, 22(1): 31-40. DOI: 10.1111/1751-2980.12957.

31.Wang Z, Wu YF, Yue ZD, et al. Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. World J Gastroenterol, 2021, 27(5): 416-427. DOI: 10.3748/wjg.v27.i5.416.

32.Yao J, Zuo L, An G, et al. Risk factors for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma and portal hypertension[J]. J Gastrointestin Liver Dis, 2015, 24(3): 301-307. DOI: 10.15403/jgld.2014.1121.243.yao.

33.柏明, 韩国宏, 原姗姗, 等. 经颈静脉肝内门体分流术后早期肝性脑病的危险因素[J]. 中华肝脏病杂志, 2011, 19(7): 498-501. [Bo M, Han GH, Yuan SS, et al. Early hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: the risk factors and long-time survival[J]. Chinese Journal of Hepatology, 2011, 19(7): 498-501.] DOI: 10.3760/cma.j.issn. 1007-3418.2011.07.008.

34.高西杰, 赵剑波, 谭卿, 等. Viatorr支架经颈静脉肝内门体分流术后显性肝性脑病发生率及其危险因素分析[J]. 介入放射学杂志, 2021, 30(10): 998-1002. [Gao XJ, Zhao JB, Tan Q, et  al. Overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with viatorr stent: analysis of its incidence and risk factors[J]. Journal of Interventional Radiology, 2021, 30(10): 998-1002.] DOI: 10.3969/j.issn.1008-794X.2021.10.007.

35.高旭东, 杨昆, 张克明, 等. 经颈静脉肝内门体静脉分流术后肝性脑病发病率的多因素分析[J]. 中国综合临床, 2019, 35(6): 498-502. [Gao XD, Yang K, Zhang  KM, et al. Multivariate analysis of the incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Clinical Medicine of China, 2019, 35(6): 498-502.] DOI: 10.3760/cma.j.issn.1008-6315.2019.06.005.

36.郭欢. 经颈静脉肝内门体分流术后并发肝性脑病的危险因素分析[D]. 厦门: 厦门大学, 2019. [Guo H. Analysis of risk factors for post-TIPS hepatic encephalopathy[D]. Xiamen: Xiamen University, 2019.] DOI: 10.27424/d.cnki.gxmdu.2019.000294.

37.史程怡. 经颈静脉肝内门体分流术后显性肝性脑病的危险因素分析[D]. 石家庄: 河北医科大学, 2023. [Shi CY. Risk factors analysis of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[D]. Shijiazhuang: Hebei Medical University, 2023.] DOI: 10.27111/d.cnki.ghyku.2023.000669.

38.王澜静, 秦建平, 姚欣, 等. 乙型肝炎肝硬化门静脉高压患者经颈静脉肝内门体分流术后显性肝性脑病风险预测模型的构建[J]. 临床肝胆病杂志, 2024, 40(6): 1149-1155. [Wang  LJ, Qin JP, Yao X, et al. Construction of a risk prediction model for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with hepatitis B cirrhosis and portal hypertension[J]. Journal of Clinical Hepatology, 2024, 40(6): 1149-1155.] DOI: 10.12449/JCH240613.

39.吴越. 经颈静脉肝内门体静脉分流术后显性肝性脑病发生的危险因素分析[D]. 太原: 山西医科大学, 2021. [Wu  Y. Analysis of risk factors for the occurrence of overt hepatic encephalopathy after transjugular intrahepatic portosystemic[D]. Taiyuan: Shanxi Medical University, 2021.] DOI: 10.27288/d.cnki.gsxyu.2021.000175.

40.晏楠, 白云飞, 单志刚, 等. 经颈内静脉肝内门体静脉分流术后肝性脑病危险因素分析[J]. 临床误诊误治, 2015, 28(7): 39-43. [Yan N, Bai YF, Shan ZG, et al. Analysis of risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Clinical Misdiagnosis & Mistherapy, 2015, 28(7): 39-43.] DOI: 10.3969/j.issn.1002-3429.2015.07.014.

41.姚运海, 罗艳, 朱京乐, 等. 急性食管胃底静脉曲张破裂出血行急诊经颈静脉肝内门体分流术后发生肝性脑病的危险因素分析[J]. 临床肝胆病杂志, 2020, 36(2): 343-347. [Yao  YH, Luo Y, Zhu JY, et al. Risk factors for hepatic encephalopathy after emergency transjugular intrahepatic portosystemic shunt for patients with acute esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2020, 36(2): 343-347.] DOI: 10.3969/j.issn. 1001-5256.2020.02.022.

42.袁巍, 李龙鹤, 韩晓玉, 等. TIPS术后发生肝性脑病的临床预测模型建立与效能分析[J]. 现代消化及介入诊疗, 2021, 26(7): 874-877. [Yuan W, Li LH, Han XY, et  al. Clinical predictive modeling and efficacy analysis of the occurrence of hepatic encephalopathy after TIPS[J]. Modern Digestion & Intervention, 2021, 26(7): 874-877.] DOI: 10.3969/j.issn.1672-2159.2021.07.017.

43.周薇, 杨晋辉. 经颈静脉肝内门体分流术后肝性脑病的相关危险因素分析[J]. 重庆医学, 2014, 43(29): 3861-3863. [Zhou  W, Yang JH. Analysis of risk factors of hepatic encephalopathy after TIPS[J]. Chongqing Medicine, 2014, 43(29): 3861-3863.] DOI: 10.3969/j.issn.1671-8348.2014.29.005.

44.卓松波, 赵卫, 胡继红, 等. 经颈静脉肝内门体分流术后显性肝性脑病发生率及危险因素分析[J]. 临床放射学杂志, 2023, 42(11): 1806-1811. [Zhuo SB, Zhao W, Hu JH, et al. Incidence and risk factors of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Radiology, 2023, 42(11): 1806-1811.] DOI: 10.13437/j.cnki.jcr.2023.11.009.

45.Yang Y, Liang X, Yang S, et al. Preoperative prediction of overt hepatic encephalopathy caused by transjugular intrahepatic portosystemic shunt[J]. Eur J Radiol, 2022, 154: 110384. DOI: 10.1016/j.ejrad.2022.110384.

46.Coronado WM, Ju C, Bullen J, et al. Predictors of occurrence and risk of hepatic encephalopathy after TIPS creation: a 15-year experience[J]. Cardiovasc Intervent Radiol, 2020, 43(8): 1156-1164. DOI: 10.1007/s00270-020-02512-7.

47.Li Y, He X, Pang H. A model to predict early hepatic encephalopathy in patients undergoing transjugular intrahepatic portosystemic shunt[J]. Turk J Gastroenterol, 2019, 30(8): 702-707. DOI: 10.5152/tjg.2019.18485.

48.Li K, Cheng Y, Zhao R, et al. Prediction of mortality and overt hepatic encephalopathy undergoing transjugular intrahepatic portosystemic shunt: a retrospective cohort study[J]. Abdom Radiol (NY), 2024, 49(3): 908-918. DOI: 10.1007/s00261-023-04086-7.

49.Liao Y, Zhang L, Wang JT, et al. A novel nomogram predicting overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in portal hypertension patients[J]. Sci Rep, 2023, 13(1): 15244. DOI: 10.1038/s41598-023-42061-w.

50.Routhu M, Safka V, Routhu SK, et al. Observational cohort study of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS)[J]. Ann Hepatol, 2017, 16(1): 140-148. DOI: 10.5604/16652681.1226932.

51.Shi W, Xu W, Fan N, et al. Body compositions correlate with overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a multicentre cohort study[J]. J Clin Gastroenterol, 2024. DOI: 10.1097/mcg. 0000000000002014.

52.Yang C, Zhu X, Liu J, et al. Development and validation of prognostic models to estimate the risk of overt hepatic encephalopathy after TIPS creation: a multicenter study[J]. Clin Transl Gastroenterol, 2022, 13(3): e00461. DOI: 10.14309/ctg. 0000000000000461.

53.Yin X, Zhang F, Guo H, et al. A nomogram to predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients[J]. Sci Rep, 2020, 10(1): 9381-9388. DOI: 10.1038/s41598-020-65227-2.

54.Yin L, Chu SL, Lv WF, et al. Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt[J]. World J Gastroenterol, 2023, 29(18): 2875-2887. DOI: 10.3748/wjg.v29.i18.2875.

55.Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study of the liver[J]. Hepatology, 2014, 60(2): 715-735. DOI: 10.1002/hep.27210.

56.Bunchorntavakul C, Reddy KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2020, 51(1): 64-77. DOI: 10.1111/apt.15571.

57.Hanai T, Shiraki M, Nishimura K, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis[J]. Nutrition, 2015, 31(1): 193-199. DOI: 10.1016/j.nut.2014.07.005.

58.Chang KV, Chen JD, Wu WT, et al. Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and Meta-analysis[J]. J Formos Med Assoc, 2019, 118(4): 833-842. DOI: 10.1016/j.jfma.2018.09.011.

59.Li J, Tang S, Zhao J, et al. Long-term survival prediction for transjugular intrahepatic portosystemic shunt in severe cirrhotic ascites: assessment of ten prognostic models[J]. Eur J Gastroenterol Hepatol, 2021, 33(12): 1547-1555. DOI: 10.1097/meg.0000000000001890.

60.Rowley MW, Choi M, Chen S, et al. Refractory hepatic encephalopathy after elective transjugular intrahepatic portosystemic shunt: risk factors and outcomes with revision[J]. Cardiovasc Intervent Radiol, 2018, 41(11): 1765-1772. DOI: 10.1007/s00270-018-1992-2.

61.Wang Q, Lv Y, Bai M, et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding[J]. J Hepatol, 2017, 67(3): 508-516. DOI: 10.1016/j.jhep.2017.05.006.

62.Luo SH, Chu JG, Huang H, et al. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy[J]. World J Gastroenterol, 2019, 25(9): 1088-1099. DOI: 10.3748/wjg.v25.i9.1088.

63.Yao X, Zhou H, Huang S, et al. Effects of transjugular intrahepatic portosystemic shunt using the viatorr stent on hepatic reserve function in patients with cirrhosis[J]. World J Clin Cases, 2021, 9(7): 1532-1542. DOI: 10.12998/wjcc.v9.i7.1532.

64.Bernardi M, Moreau R, Angeli P, et al. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis[J]. J Hepatol, 2015, 63(5): 1272-1284. DOI: 10.1016/j.jhep.2015. 07.004.

65.Adlakha N, Russo MW. Outcomes after transjugular intrahepatic portosystemic shunt in cirrhotic patients 70 years and older[J]. J Clin Med, 2020, 9(2): 381. DOI: 10.3390/jcm9020381.

66.Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy[J]. Nat Rev Gastroenterol Hepatol, 2010, 7(9): 515-525. DOI: 10.1038/nrgastro.2010.116.

67.Lv Y, Chen H, Luo B, et al. Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(8): 736-746. DOI: 10.1016/s2468-1253(22)00087-5.

68.林熔, 郭霞. 肝硬化EVB患者TIPS术后发生肝性脑病的危险因素分析及循证护理措施探究[J]. 中国医药指南, 2023, 21(22): 168-170. [Lin R, Guo X. Risk factors for hepatic encephalopathy after TIPS in EVB patients with liver cirrhosis and evidence-based nursing measures[J]. Guide of China Medicine, 2023, 21(22): 168-170.] DOI: 10.15912/j.cnki.gocm.2023.22.014.

69.Dam G, Vilstrup H, Watson H, et al. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites[J]. Hepatology, 2016, 64(4): 1265-1272. DOI: 10.1002/hep.28737.

70.Tsai CF, Chen MH, Wang YP, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study[J]. Gastroenterology, 2017, 152(1): 134-141. DOI: 10.1053/j.gastro.2016.09.007.

71.Nardelli S, Lattanzi B, Merli M, et al. Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis[J]. Hepatology, 2019, 70(5): 1704-1713. DOI: 10.1002/hep.30692.

72.Häussinger D, Sies H. Hepatic encephalopathy: clinical aspects and pathogenetic concept[J]. Arch Biochem Biophys, 2013, 536(2): 97-100. DOI: 10.1016/j.abb.2013.04.013.

73.Lockwood AH. Blood ammonia levels and hepatic encephalopathy[J]. Metab Brain Dis, 2004, 19(3): 345-349. DOI: 10.1023/b:mebr.0000043980.74574.eb.

74.Senzolo M, Zarantonello L, Formentin C, et al. Predictive value of induced hyperammonaemia and neuropsychiatric profiling in relation to the occurrence of post-TIPS hepatic encephalopathy[J]. Metab Brain Dis, 2019, 34(6): 1803-1812. DOI: 10.1007/s11011-019-00490-5.

75.中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南[J]. 临床肝胆病杂志, 2018, 34(10): 2076-2089. [Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(10): 2076-2089.] DOI: 10.3969/j.issn.1001-5256.2018.10.007.

76.Ma Y, Du L, Zhou S, et al. Association of direct bilirubin to total bilirubin ratio with 90-day mortality in patients with acute-on-chronic liver failure[J]. Front Med (Lausanne), 2023, 10: 1286510. DOI: 10.3389/fmed.2023.1286510.

77.Bossen L, Ginès P, Vilstrup H, et al. Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites[J]. J Gastroenterol Hepatol, 2019, 34(5): 914-920. DOI: 10.1111/jgh.14558.